8-K: REGEN BIOPHARMA Issues Shares for Debt, Fees

REGEN BIOPHARMA, INC. issued 77.8 million common shares to satisfy convertible debt principal, accrued interest, and incurred fees.

Summary

• REGEN BIOPHARMA, INC. issued 77,849,847 common shares between February 4, 2026, and February 27, 2026.
• These shares were issued to satisfy $53,474 of principal convertible indebtedness.
• An additional $4,249 of accrued interest on convertible indebtedness was satisfied.
• The issuance also covered $11,000 in incurred fees.
• The total value satisfied by the share issuance was $68,723.
• The shares were issued under Section 4(a)(2) of the Securities Act of 1933, indicating an unregistered private placement.
• No underwriters were involved, and no commissions or advertising were used.
• As of March 3, 2026, the company has 212,318,424 common shares issued and outstanding.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development due to extreme shareholder dilution at a very low implied share price, indicating potential financial distress and significant value erosion for existing shareholders.

Positives

• The company successfully converted convertible indebtedness and settled fees by issuing equity, reducing its debt obligations.

Negatives

• The issuance of 77,849,847 new common shares represents significant dilution for existing shareholders, increasing the total outstanding shares to 212,318,424.
• The conversion rate implies a very low share price (approximately $0.00088 per share), which is a significant concern for valuation and existing shareholder equity.

Risks

• Significant shareholder dilution due to the issuance of a large number of shares to satisfy debt and fees.
• Potential downward pressure on share price due to the increased supply of shares and the extremely low implied conversion price.
• The company's reliance on equity issuance to satisfy debt obligations may indicate limited cash flow or access to more favorable financing options.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Management Comments

• The shares were sold directly through our management.
• No commission or other consideration was paid in connection with the sale of the shares.
• There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.

Industry Context

StockSavvy.ai notes that biopharma companies, especially those in early stages or with limited revenue, often rely on equity financing to fund operations, research, and development. Converting debt to equity can be a common strategy to manage cash flow, but significant dilution can be a concern for investors, particularly if the implied conversion price is very low, as appears to be the case here.

Comparison to Industry Standards

• The issuance of a large number of shares (77.8 million) for a relatively small amount of debt ($68,723 total) suggests a very low implied share price (approximately $0.00088 per share). This is significantly below typical trading prices for most publicly listed companies, even micro-cap biotechs, and could indicate severe financial distress or a highly speculative valuation.
• Compared to industry peers like small-cap biotech companies that might raise capital at prices ranging from a few cents to several dollars per share, this conversion implies a valuation that is extremely low, potentially signaling a 'penny stock' status or worse.
• The substantial increase in outstanding shares (from an implied ~134 million to 212 million, an increase of ~58%) is a high dilution rate for a single transaction, which is generally viewed negatively by investors unless it's tied to a major value-creating event.

Stakeholder Impact

• Shareholders: Significant dilution of existing shareholders' ownership percentage and potential downward pressure on share price due to the large number of new shares issued at a very low implied valuation.
• Creditors: Convertible debt holders who converted their debt into equity have had their claims satisfied, reducing the company's debt burden.

Key Dates

Recommendation

The issuance of a massive number of shares (77.8 million) to satisfy a relatively small amount of debt and fees ($68,723 total) at an implied price of less than one-tenth of a cent per share is indicative of severe financial distress and extreme dilution. This transaction significantly devalues existing equity and suggests a company struggling to manage its liabilities without severely impacting shareholder value. Such a move typically signals a lack of viable financing alternatives and a highly unfavorable risk-reward profile for current and prospective investors.

Keywords

REGEN BIOPHARMA, equity issuance, debt conversion, dilution, 8-K filing, unregistered sales, common shares, convertible debt, private placement